NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

Compare
892.78 +7.77 (+0.88%)
As of 11:52 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
35,932,100.00
34,124,100.00
28,541,400.00
28,318,400.00
24,539,800.00
--
Cost of Revenue
7,129,000.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
--
Gross Profit
28,803,100.00
27,041,900.00
21,911,600.00
21,005,600.00
19,056,500.00
--
Operating Expense
16,995,000.00
16,254,600.00
13,258,300.00
13,072,600.00
11,955,100.00
--
Operating Income
11,808,100.00
10,787,300.00
8,653,300.00
7,933,000.00
7,101,400.00
--
Net Non Operating Interest Income Expense
-377,500.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
--
Other Income Expense
-3,869,600.00
-3,920,400.00
-1,578,100.00
-1,463,100.00
455,100.00
--
Pretax Income
7,561,000.00
6,554,600.00
6,806,400.00
6,155,500.00
7,229,900.00
--
Tax Provision
1,422,600.00
1,314,200.00
561,600.00
573,800.00
1,036,200.00
--
Net Income Common Stockholders
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
--
Diluted NI Available to Com Stockholders
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
--
Basic EPS
6.82
5.52
6.57
5.85
6.47
--
Diluted EPS
6.79
5.52
6.57
5.85
6.47
--
Basic Average Shares
900,131.00
949,379.00
950,182.00
953,653.00
956,590.00
--
Diluted Average Shares
903,409.00
949,379.00
950,182.00
953,653.00
956,590.00
--
Total Expenses
24,124,000.00
23,336,800.00
19,888,100.00
20,385,400.00
17,438,400.00
--
Net Income from Continuing & Discontinued Operation
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
--
Normalized Income
9,274,983.57
8,346,672.30
7,678,804.60
6,955,351.50
5,636,135.80
--
Interest Income
185,200.00
173,600.00
62,800.00
25,400.00
33,000.00
--
Interest Expense
562,700.00
485,900.00
331,600.00
339,800.00
359,600.00
--
Net Interest Income
-377,500.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
--
EBIT
8,123,700.00
7,040,500.00
7,138,000.00
6,495,300.00
7,589,500.00
--
EBITDA
9,689,300.00
8,567,800.00
8,660,500.00
8,042,900.00
8,913,400.00
--
Reconciled Cost of Revenue
7,129,000.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
--
Reconciled Depreciation
1,565,600.00
1,527,300.00
1,522,500.00
1,547,600.00
1,323,900.00
--
Net Income from Continuing Operation Net Minority Interest
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
--
Total Unusual Items Excluding Goodwill
-3,863,500.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
--
Total Unusual Items
-3,863,500.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
--
Normalized EBITDA
13,552,800.00
12,455,500.00
10,224,300.00
9,557,400.00
8,262,800.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-726,916.43
-781,427.70
-129,795.40
-140,848.50
93,035.80
--
12/31/2019 - 6/1/1972

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PFE Pfizer Inc.
27.35
+1.35%
 
MRK Merck & Co., Inc.
127.88
+0.30%
 
ABBV AbbVie Inc.
171.60
+1.13%
 
JNJ Johnson & Johnson
145.65
-0.21%
 
AMGN Amgen Inc.
304.26
+0.32%
 
BMY Bristol-Myers Squibb Company
40.58
-0.96%
 
AZN AstraZeneca PLC
78.76
-0.70%
 
GILD Gilead Sciences, Inc.
63.15
-1.74%
 
BIIB Biogen Inc.
227.22
+0.34%
 
NVS Novartis AG
105.15
+0.21%